Pregnancies in women with lupus nephritis are at high-risk of complications, while scarcity of scientific knowledge on prognostic factors impedes a fair medical counseling. We aimed to identify determinants associated with maternal and fetal complications.
Study Identifies 10 most important contemporary challenges in the management of SLE
New Study Assesses Shingles Frequency in People Receiving CYC and Steroids
People who have lupus and systemic vasculitis have weakened immune systems that are more susceptible to infections. Side effects of medication intended to help manage these diseases, specifically steroids and chemotherapeutics, can weaken the immune system further.
Specifically, they are at an increased risk for varicella-zoster virus (VZV) reactivation. VZV is the virus, which can cause chickenpox (varicella) and shingles (zoster). Once a person recovers from chickenpox, VZV remains inactive in the body. VZV can reactivate and cause a painful rash called shingles. There are many reasons why the virus can reactivate.
French Lupus Vaccine Ready to Move Into Phase III
Neovacs, a French biotech, obtained positive Phase IIb results showing its lupus vaccine could be effective in treating this severe autoimmune disease.
Its lupus vaccine works by stimulating the patient’s immune system to produce antibodies against a protein called IFNα that regulates the immune system and is involved in the disease.
New hope for lupus patients
A clinical trial with 149 patients suffering from systemic lupus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France.